Sepsis is a significant life-threatening condition with 48.9 million cases per year leading to 11 million deaths worldwide1. Patient outcomes are directly related to the timely diagnosis and identification of the pathogen and administration of the appropriate antibiotic treatment.

Blood liquid biopsy contains circulating cell-free DNA (cfDNA), a portion of which may be shed from tumors. This circulating tumor-derived DNA (ctDNA) can be tested to identify cancerous mutations. DNAe is developing the first rapid, sample-to-result, NGS-based solution.

DNAe, the next generation sequencing (NGS) company developing a novel diagnostics platform for use at the point-of-need, announces that it will be presenting new clinical data on testing applications in cancer monitoring, bloodstream infection (BSI) detection and combatting antimicrobial resistance (AMR).

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, provides a business update on its LiDia-SEQ™ technology platform, and operational activities as the Company accelerates preparation of its commercialization strategy and roadmap.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has expanded its Commercial team, appointing Supriya Mathur to the newly created role of Global Head of Communications.

DNAe co-founder Professor Christofer Toumazou has been officially announced as a laureate of the 2021 UNESCO-Equatorial Guinea International Prize for Research in the Life Sciences – the first UK winner.

Together with Imperial College London (‘Imperial’), DNAe has been awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to support development of its next generation sequencing (NGS)-based diagnostic platform for use in cancer monitoring.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announces positive results from internal tests using its LiDia-SEQ™ sequencing technology to identify SARS-CoV-2. The SARS-CoV-2 coronavirus is the cause of the COVID-19 pandemic currently causing extensive mortality, morbidity and disruption globally.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announced that the US Food and Drug Administration (FDA) has granted it a “Breakthrough Device” designation for its pioneering platform and first assay.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today provides an update on its response to the COVID-19 pandemic and announces that internal testing is underway to evaluate use of the LiDia-SEQ™ sequencing technology for the current SARS-CoV-2 pandemic and to help in containing future outbreaks.

DNAe, the next generation sequencing (NGS) company developing novel diagnostics for use at the point-of-need, provides an update on its significant research and development (R&D) and operational achievements in 2019.